Next Article in Journal
Post-Transcriptional Control of Type I Interferon Induction by Porcine Reproductive and Respiratory Syndrome Virus in Its Natural Host Cells
Next Article in Special Issue
Transcriptional Regulation of Latent Feline Immunodeficiency Virus in Peripheral CD4+ T-lymphocytes
Previous Article in Journal
Poxvirus Cell Entry: How Many Proteins Does it Take?
Previous Article in Special Issue
Feline Immunodeficiency Virus in South America

Pharmacological Inhibition of Feline Immunodeficiency Virus (FIV)

Department of Pathobiology, University of Guelph, Guelph, Ontario N1G 2W1, Canada
Author to whom correspondence should be addressed.
Received: 2 April 2012 / Revised: 18 April 2012 / Accepted: 20 April 2012 / Published: 27 April 2012
(This article belongs to the Special Issue Feline Retroviruses)
Feline immunodeficiency virus (FIV) is a member of the retroviridae family of viruses and causes an acquired immunodeficiency syndrome (AIDS) in domestic and non-domestic cats worldwide. Genome organization of FIV and clinical characteristics of the disease caused by the virus are similar to those of human immunodeficiency virus (HIV). Both viruses infect T lymphocytes, monocytes and macrophages, and their replication cycle in infected cells is analogous. Due to marked similarity in genomic organization, virus structure, virus replication and disease pathogenesis of FIV and HIV, infection of cats with FIV is a useful tool to study and develop novel drugs and vaccines for HIV. Anti-retroviral drugs studied extensively in HIV infection have targeted different steps of the virus replication cycle: (1) inhibition of virus entry into susceptible cells at the level of attachment to host cell surface receptors and co-receptors; (2) inhibition of fusion of the virus membrane with the cell membrane; (3) blockade of reverse transcription of viral genomic RNA; (4) interruption of nuclear translocation and viral DNA integration into host genomes; (5) prevention of viral transcript processing and nuclear export; and (6) inhibition of virion assembly and maturation. Despite much success of anti-retroviral therapy slowing disease progression in people, similar therapy has not been thoroughly investigated in cats. In this article we review current pharmacological approaches and novel targets for anti-lentiviral therapy, and critically assess potentially suitable applications against FIV infection in cats. View Full-Text
Keywords: antiretroviral therapy; feline immunodeficiency virus; HIV antiretroviral therapy; feline immunodeficiency virus; HIV
Show Figures

Graphical abstract

MDPI and ACS Style

Mohammadi, H.; Bienzle, D. Pharmacological Inhibition of Feline Immunodeficiency Virus (FIV). Viruses 2012, 4, 708-724.

AMA Style

Mohammadi H, Bienzle D. Pharmacological Inhibition of Feline Immunodeficiency Virus (FIV). Viruses. 2012; 4(5):708-724.

Chicago/Turabian Style

Mohammadi, Hakimeh; Bienzle, Dorothee. 2012. "Pharmacological Inhibition of Feline Immunodeficiency Virus (FIV)" Viruses 4, no. 5: 708-724.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Search more from Scilit
Back to TopTop